Hematopoietic stem cell therapy for malignant diseases

Annals of Medicine

Volumn 39, Issue 6, 2007, Pages 465-473

  Shapira, Michael Y ^a   Hai, Ali Abdul ^a   Tsirigotis, Panagiotis ^a   Resnick, Igor B ^a   Or, Reuven ^a   Slavin, Shimon ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

Donor lymphocyte infusion (DLI); Graft versus host disease (GVHD); Graft versus leukemia (GVL); Graft versus tumor (GVT) effects; Nonmyeloablative conditioning; Nonmyeloablative stem cell transplantation (NST); Reduced intensity conditioning (RIC)

Indexed keywords

ALEMTUZUMAB; BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; ETOPOSIDE; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; MELPHALAN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; THYMOCYTE ANTIBODY;

ALLOGENEIC STEM CELL TRANSPLANTATION; AUTOLOGOUS STEM CELL TRANSPLANTATION; BREAST CANCER; CANCER; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CANCER THERAPY; DONOR LYMPHOCYTE INFUSION; GERM CELL TUMOR; GRAFT VERSUS HOST REACTION; GROUPS BY AGE; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH RISK PATIENT; HLA MATCHING; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTERMETHOD COMPARISON; KIDNEY CARCINOMA; LOW DRUG DOSE; LUNG CANCER; LUNG NON SMALL CELL CANCER; LYMPHOMA; MYELOABLATIVE CONDITIONING; NEUTROPENIA; NONHUMAN; NONMYELOABLATIVE CONDITIONING; OVARY CANCER; PANCREAS CANCER; PRIORITY JOURNAL; REVIEW; SOLID TUMOR; T LYMPHOCYTE ACTIVATION; THROMBOCYTOPENIA; WHOLE BODY RADIATION;

GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; TRANSPLANTATION CONDITIONING;

EID: 34748844588     PISSN: 07853890     EISSN: 16512219     Source Type: Journal    
DOI: 10.1080/07853890701472323     Document Type: Review

References (60)

1. Appelbaum FR, Thomas ED. Treatment of acute leukemia in adults with chemoradiotherapy and bone marrow transplantation. Cancer. 1985;55:2202-09
2. Sinkovics JG, Shullenberger CC. Effect of hematopoietic chimerism on the course of Rauscher's viral mouse leukemia. Proc Am Assoc Cancer Res. 1963;4:62-72.
3. Boranic M, Tonkovic I. Time pattern of the antileukemia effect of graft-vs-host reaction in mice. I. Cellular events. Cancer Res. 1971;31:1140-7.
4. Weiden PL, Fluornoy N, Sanders JE, Sullivan KM, Thomas ED. Anti-leukemic effect of graft-versus-host disease contributes to improved survival after allogeneic marrow transplantation. Transplantation. 1981;13:248-51.
5. Slavin S, Or R, Naparstek E, Ackerstein A, Weiss L. Cellular-mediated immunotherapy of leukemia in conjunction with autologous and allogeneic bone marrow transplantation in experimental animals and man. Blood. 1988;72 suppl 1:407a.
6. Slavin S, Naparstek E, Nagler A, Ackerstein A, Kapelushnik J, Brautbar C, et al. Allogeneic cell therapy for relapsed leukemia following bone marrow transplantation with donor peripheral blood lymphocytes. Exp Hematol. 1995;23:1553-62.
7. Slavin S, Naparstek E, Nagler A, Akerstein A, Samuel S, Kapelushnik J, et al. Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse after post allogeneic bone marrow transplantation. Blood. 1996;87:2195-204.
8. Gratwohl A, Hermans J, Goldman JM, Arcese W, Carreras E, Devergie A, et al. Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Lancet. 1998;352:1087-92.
9. Passweg JR, Rowlings PA, Armitage JO, Gale RP, Pelz CJ, Sobocinski AK, et al. Report from the International Bone Marrow Transplant Registry and Autologous Blood and Marrow Transplant Registry - North America. Clin Transpl, 117-27.
10. Sullivan KM, Weiden PL, Storb R, Witherspoon RP, Fefer A, Fisher L, et al. Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia. Blood. 1989;73:1720-6.
11. Horowitz M, Gale RP, Sondel PM, Goldman JM, Kersey J, Kolb HJ, et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood. 1990;75:555-62.
12. Ringden O, Horowitz MM. for the Advisory Committee of the International BMT Registry. Graft-versus-leukemia reactions in humans. Transplant Proc. 1989;21:2989-92.
13. Kolb HJ, Mittermuller J, Clemm C, Holler E, Ledderose G, Brehm G, et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood. 1990;76:2462-5.
14. Kolb HJ, Schattenberg A, Goldman JM, Hertenstein B, Jacobsen N, Arcese W, et al. Working Party Chronic Leukemia, Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients: European Group for blood and marrow transplantation. Blood. 1995;86:2041-50.
15. Collins RH Jr, Shpilberg O, Drobyski WR, Porter DL, Giralt S, Champlin R, et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol. 1997;15:433-44.
16. Porter DL, Roth MS, McGarigle C, Ferrara JL, Antin JH. Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia. New Engl J Med. 1994;330:100-06.
17. Mackinnon S, Papadopoulos EB, Carabassi MH, Reich L, Collins NH, Boulad F, et al. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease. Blood. 1995;86:1261-8.
18. Weiss L, Lubin I, Factorowich Y, Lapidot Z, Reich S, Reisner , et al. Effective graft vs leukemia effects independent of graft vs host disease after T-Cell depleted allogeneic bone marrow transplantation in a murine model of B Cell leukemia/lymphoma. Role of cell therapy and rIL-2. J Immunol. 1994;153:2562-7.
19. Slavin S, Weiss L, Morecki S, Weingensberg M. Eradication of murine leukemia with histoincompatible marrow grafts in mice conditioned with total lymphoid irradiation (TLI). Cancer Immunol Immunother. 1981;11:155-61.
20. Moscovitch M, Slavin S. Anti-tumor effects of allogeneic bone marrow transplantation in (NZB/NZW) F1 hybrids with spontaneous lymphosarcoma. J Immunol. 1984;132:997-1000.
21. Slavin S, Nagler A, Naparstek E, Kapelushnik J, Aker M, Cividalli G, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood. 1998;91:756-63.
22. Giralt S, Thall PF, Khouri I, Wang X, Braunschweig I, Ippolitti C, et al. Melphalan and purine-analog containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood. 2001;97:631-7.
23. Kottaridis PD, Milligan DW, Chopra R, Chakraverty RK, Chakrabarti S, Robinson S, et al. In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation. Blood. 2000;96:2419-25.
24. Sayer HG, Kroger M, Beyer J, Kiehl M, Klein SA, Schaefer-Eckhart K, et al. Reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia: disease status by marrow blasts is the strongest prognostic factor. Bone Marrow Transplant. 2003;31:1089-95.
25. Bacigalupo A. Third EBMT/AMGEN Workshop on reduced-intensity conditioning allogeneic hematopoietic stem cell transplants (RIC-HSCT), and panel consensus. Bone Marrow Transplant. 2004;33:691-6.
26. McSweeney PA, Niederwieser D, Shizuru JA, Sandmaier BM, Molina AJ, Maloney G, et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood. 2001;97:3390-400.
27. Niederwieser D, Maris M, Shizuru JA, Petersdorf E, Hegenbart U, Sandmaier BM, et al. Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases. Blood. 2003;101:1620-9.
28. Shapira MY, Or R, Resnick IB, Bitan M, Ackerstein A, Samuel S, et al. A new minimally ablative stem cell transplantation procedure in high-risk patients not eligible for nonmyeloablative allogeneic bone marrow transplantation. Bone Marrow Transplant. 2003;32:557-61.
29. Alyea EP, Kim HT, Ho V, Cutler C, Gribben J, DeAngelo DJ, et al. Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age. Blood. 2005;105:1810-14.
30. Diaconescu R, Flowers CR, Storer B, Sorror ML, Maris MB, Maloney DG, et al. Morbidity and mortality with nonmyeloablative compared with myeloablative conditioning before hematopoietic cell transplantation from HLA-matched related donors. Blood. 2004;104:1550-8.
31. Sorror ML, Maris MB, Storer B, Sandmaier BM, Diaconescu R, Flowers C, et al. Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning: influence of pretransplantation comorbidities. Blood. 2004;104:961-8.
32. Valcarcel D, Martino R, Sureda A, Canals C, Altes A, Briones J, et al. Conventional versus reduced-intensity conditioning regimen for allogeneic stem cell transplantation in patients with hematological malignancies. Eur J Haematol. 2005;74:144-51.
33. Canals C, Martino R, Sureda A, Altes A, Briones J, Subira M, et al. Strategies to reduce transplant-related mortality after allogeneic stem cell transplantation in elderly patients: Comparison of reduced-intensity conditioning and unmanipulated peripheral blood stem cells vs a myeloablative regimen and CD34+ cell selection. Exp Hematol. 2003;31:1039-43.
34. Perez-Simon JA, Diez-Campelo M, Martino R, Brunet S, Urbano A, Caballero MD, et al. Influence of the intensity of the conditioning regimen on the characteristics of acute and chronic graft-versus-host disease after allogeneic transplantation. Br J Haematol. 2005;130:394-403.
35. Mielcarek M, Martin PJ, Leisenring W, Flowers ME, Maloney DG, Sandmaier BM, et al. Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. Blood. 2003;102:756-62.
36. Vela-Ojeda J, Garcia-Ruiz Esparza MA, Tripp-Villanueva F, Ayala-Sanchez M, Delgado-Lamas JL, Graces-Ruiz O, et al. Allogeneic peripheral blood stem cell transplantation using reduced intensity versus myeloablative conditioning regimens for the treatment of leukemia. Stem Cells Dev. 2004;13:571-9.
37. Massenkeil G, Nagy M, Neuburger S, Tamm I, Lutz C, le Coutre P, et al. Survival after reduced-intensity conditioning is not inferior to standard high-dose conditioning before allogeneic haematopoietic cell transplantation in acute leukaemias. Bone Marrow Transplant. 2005;36:683-9.
38. Couriel DR, Saliba RM, Giralt S, Khouri I, Andersson B, de Lima M, et al. Acute and chronic graft-versus-host disease after ablative and nonmyeloablative conditioning for allogeneic hematopoietic transplantation. Biol Blood Marrow Transplant. 2004;10:178-85.
39. Dreger P, Brand R, Milligan D, Corradini P, Finke J, Lambertenghi DG, et al. Chronic Leukemia Working Party of the EBMT. Reduced-intensity conditioning lowers treatment-related mortality of allogeneic stem cell transplantation for chronic lymphocytic leukemia: a population-matched analysis. Leukemia. 2005;19:1029-33.
40. Aoudjhane M, Labopin M, Gorin NC, Shimoni A, Ruutu T, Kolb HJ, et al. Acute Leukemia Working Party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT). Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey from the Acute Leukemia Working Party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT). Leukemia. 2005;19:2304-12.
41. Wong R, Giralt SA, Martin T, Couriel DR, Anagnostopoulous A, Hosing C, et al. Reduced intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years. Blood. 2003;102:3052-9.
42. Shapira MY, Resnick IB, Bitan M, Ackerstein A, Samuel S, Elad S, et al. Low transplant related mortality with allogeneic stem cell transplantation in elderly patients. Bone Marrow Transplant. 2004;34:155-9.
43. Bertz H, Potthoff K, Finke J. Allogeneic stem cell transplantation from related and unrelated donors in older patients with myeloid leukemia. J Clin Oncol. 2003;21:1480-4.
44. Shimoni A, Kroger N, Zabelina T, Ayuk F, Hardan I, Yeshurun M, et al. Hematopoietic stem cell transplantation from unrelated donors in elderly patients (age>55 years) with hematologic malignancies: older age is no longer a contraindication when using a reduced intensity conditioning. Leukemia. 2005;19:7-12.
45. Eibl B, Schwaighofer H, Nachbaur D, Marth C, Gachter A, Knapp R, et al. Evidence for a graft-versus-tumor effect in a patient treated with marrow ablative chemotherapy and allogeneic bone marrow transplantation for breast cancer. Blood. 1996;88:1501-08.
46. Childs R, Chernoff A, Contentin N, Bahceci E, Schrump D, Leitman S, et al. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med. 2000;343:750-8.
47. Nakagawa T, Kami M, Hori A, Kim SW, Murashinge N, Hamaki T, et al. Allogeneic hematopoietic stem cell transplantation with a reduced-intensity conditioning regimen for treatment of metastatic renal cell carcinoma: single institution experience with a minimum 1-year follow-up. Exp Hematol. 2004;32:599-606.
48. Bay JO, Fleury J, Choufi B, Bilger K, Tournilhac O, Vey N, et al. Allogeneic hematopoietic stem cell transplantation in ovarian carcinoma: results of five patients. Bone Marrow Transplant. 2002;30:95-102.
49. Ueno NT, Cheng YC, Rondon G, Tannir NM, Gajewski JL, Couriel DR, et al. Rapid induction of complete donor chimerism by the use of a reduced-intensity conditioning regimen composed of fludarabine and melphalan in allogeneic stem cell transplantation for metastatic solid tumors. Blood. 2003;102:3829-36.
50. Carella AM, Beltrami G, Corsetti MT, Nati S, Musto P, Scalzulli P, et al. Reduced intensity conditioning for allograft after cytoreductive autograft in metastatic breast cancer. Lancet. 2005;366:318-20.
51. Kanda Y, Komatsu Y, Akahane M, Kojima S, Asano-Mori Y, Tada M, et al. Graft-versus-tumor effect against advanced pancreatic cancer after allogeneic reduced-intensity stem cell transplantation. Transplantation. 2005;79:821-7.
52. Pedrazzoli P, Da Prada GA, Giorgiani G, Schiavo R, Zambelli A, Giraldi E, et al. Allogeneic blood stem cell transplantation after a reduced-intensity, preparative regimen: a pilot study in patients with refractory malignancies. Cancer. 2002;94:2409-15.
53. Moscardo F, Martinez JA, Sanz GF, Jimenez C, Cervera J, Sanchis J, et al. Graft-versus-tumour effect in non-small-cell lung cancer after allogeneic peripheral blood stem cell transplantation. Br J Haematol. 2000;111:708-10.
54. Kurokawa T, Fischer K, Bertz H, Hoegerle S, Finke J, Mackensen A. In vitro and in vivo characterization of graft-versus-tumor responses in melanoma patients after allogeneic peripheral blood stem cell transplantation. Int J Cancer. 2002;101:52-60.
55. Godfrey WR, Krampf MR, Taylor PA, Blazar BR. Ex vivo depletion of alloreactive cells based on CFSE dye dilution, activation antigen selection, and dendritic cell stimulation. Blood. 2004;103:1158-65.
56. Carlen S, Gilljam M, Chambers BJ, Aschan J, Guven H, Ljunggren HG, et al. A new method for in vitro expansion of cytotoxic human CD3- CD56+ natural killer cells. Hum Immunol. 2001;62:1092-8.
57. Mutis T, Verdijk R, Schrama E, Esendam B, Brand A, Goulmy E. Feasibility of immunotherapy of relapsed leukemia with ex vivo-generated cytotoxic T lymphocytes specific for hematopoietic system-restricted minor histocompatibility antigens. Blood. 1999;93:2336-41.
58. Naparstek E. The role of the anti-CD20 antibody rituximab in hematopoietic stem cell transplantation for non-Hodgkin's lymphoma. Curr Hematol Rep. 2005;4:276-83.
59. Nath SV, Seymour JF. Cure of a patient with profoundly chemotherapy-refractory primary mediastinal large B-cell lymphoma: role of rituximab, high-dose therapy, and allogeneic stem cell transplantation. Leuk Lymphoma. 2005;46:1075-9.
60. Prigozhina TB, Elkin G, Khitrin S, Slavin S. Depletion of donor-reactive cells as a new concept for improvement of mismatched bone marrow engraftment using reduced-intensity conditioning. Exp Hematol. 2004;32:1110-17.